SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

[1]  Kai Zhao,et al.  Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[2]  L. Garmire,et al.  Prediction of repurposed drugs for treating lung injury in COVID-19 , 2020, F1000Research.

[3]  H. Nishisaki,et al.  Humidifier Use and Prone Positioning in a Patient with Severe COVID-19 Pneumonia and Endotracheal Tube Impaction Due to Highly Viscous Sputum , 2020, Cureus.

[4]  The “Three Italy” of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia , 2020, Journal of NeuroVirology.

[5]  A. Basu,et al.  Faculty Opinions recommendation of SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[6]  Jianping Li,et al.  Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 , 2020, Chronic Diseases and Translational Medicine.

[7]  A. Barabasi,et al.  Network medicine framework for identifying drug-repurposing opportunities for COVID-19 , 2020, Proceedings of the National Academy of Sciences.

[8]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[9]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[10]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[11]  M. Koopmans,et al.  A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. , 2020, The New England journal of medicine.

[12]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[13]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  Lisa E. Gralinski,et al.  Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection , 2019, Journal of Virology.

[15]  A. Walls,et al.  Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors , 2019, Nature Structural & Molecular Biology.

[16]  V. Corman,et al.  Coronaviren als Ursache respiratorischer Infektionen , 2019, Der Internist.

[17]  Yukiko Shimizu,et al.  TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection , 2019, Journal of Virology.

[18]  M. Hoffmann,et al.  Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein , 2018, Scientific Reports.

[19]  B. Graham,et al.  Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization , 2018, Journal of Virology.

[20]  Sudhir Kumar,et al.  MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. , 2018, Molecular biology and evolution.

[21]  K. Shirato,et al.  Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry , 2017, Virology.

[22]  Inga Nehlmeier,et al.  The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells , 2017, PloS one.

[23]  M. Tortorici,et al.  Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein , 2017, Proceedings of the National Academy of Sciences.

[24]  S. Perlman,et al.  Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. , 2017, Annual review of medicine.

[25]  W. Baumgärtner,et al.  The differentiated airway epithelium infected by influenza viruses maintains the barrier function despite a dramatic loss of ciliated cells , 2016, Scientific Reports.

[26]  K. Shirato,et al.  Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry , 2016, Journal of Virology.

[27]  S. Perlman,et al.  Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism , 2016, Proceedings of the National Academy of Sciences.

[28]  Makoto Takeda,et al.  Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay , 2016, Antimicrobial Agents and Chemotherapy.

[29]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[30]  R. Baric,et al.  Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus , 2015, Journal of Virology.

[31]  Yanchen Zhou,et al.  Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.

[32]  R. Baric,et al.  Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus , 2014, Proceedings of the National Academy of Sciences.

[33]  J. Epstein,et al.  Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.

[34]  C. Schwegmann-Wessels,et al.  Differential Sensitivity of Bat Cells to Infection by Enveloped RNA Viruses: Coronaviruses, Paramyxoviruses, Filoviruses, and Influenza Viruses , 2013, PloS one.

[35]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[36]  Christian Drosten,et al.  The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies , 2013, Journal of Virology.

[37]  U. Buchholz,et al.  Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[38]  P. Nelson,et al.  Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts , 2012, PloS one.

[39]  L. van der Hoek,et al.  Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry , 2012, Journal of Virology.

[40]  G. Zimmer,et al.  A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon , 2011, PloS one.

[41]  Christian Drosten,et al.  Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response , 2011, Journal of Virology.

[42]  Jincun Zhao,et al.  A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry , 2010, Journal of Virology.

[43]  Makoto Takeda,et al.  Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2 , 2010, Journal of Virology.

[44]  K. Schughart,et al.  TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells , 2010, Journal of Virology.

[45]  T. Sasazuki,et al.  Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry , 2008, Proceedings of the National Academy of Sciences.

[46]  Yan Liu,et al.  Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine , 2007, Antiviral therapy.

[47]  Shibo Jiang,et al.  Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design , 2006, Journal of Virology.

[48]  Wei Liu,et al.  Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.

[49]  P. Nelson,et al.  Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease , 2006, Molecular and Cellular Biology.

[50]  Kwok-Hung Chan,et al.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[52]  S. Diamond,et al.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Bo Zhang,et al.  Multiple organ infection and the pathogenesis of SARS , 2005, The Journal of experimental medicine.

[54]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[55]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[56]  Ben Berkhout,et al.  Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Chengsheng Zhang,et al.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.

[58]  Michelle M. Packard,et al.  Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan , 2005, Human Pathology.

[59]  K. Überla,et al.  S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients , 2004, Journal of Virology.

[60]  G. Fey,et al.  Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor , 2004, Biochemical and Biophysical Research Communications.

[61]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[62]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[63]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[64]  Lin-Fa Wang,et al.  Membrane Fusion Tropism and Heterotypic Functional Activities of the Nipah Virus and Hendra Virus Envelope Glycoproteins , 2002, Journal of Virology.

[65]  A. Look,et al.  Human aminopeptidase N is a receptor for human coronavirus 229E , 1992, Nature.